Sotera Health (SHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock
Sotera Health Company SHC shares soared 8.2% in the last trading session to close at $14.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.7% loss over the past four weeks.
Sotera Health scored a strong price increase on investors’ optimism surrounding the company’s robust fourth quarter financial performance. The company reported net revenues of $1.16 billion, up 5.7% year over year. The metric surpassed the Zacks Consensus Estimate by 1.4%. Adjusted EBITDA increased 8.2% to $594 million in 2025.
This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +21.4%. Revenues are expected to be $271.98 million, up 6.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Sotera Health, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SHC going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Sotera Health belongs to the Zacks Medical Services industry. Another stock from the same industry, Teladoc TDOC, closed the last trading session 6% higher at $5.45. Over the past month, TDOC has returned -0.4%.
Teladoc's consensus EPS estimate for the upcoming report has changed +7.4% over the past month to -$0.3. Compared to the company's year-ago EPS, this represents a change of -57.9%. Teladoc currently boasts a Zacks Rank of #3 (Hold).
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
